Targeted Therapy for Blood Cancer Patients
The FDA approved a molecularly targeted therapy to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. The...
Progress Against Cancer
The FDA approved a molecularly targeted therapy to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. The...
The FDA approved zanubrutinib to treat patients with mantle cell lymphoma, an aggressive type of non-Hodgkin lymphoma. The U.S....
The FDA approval of the combination therapy further expands the number of cancers that can be treated with pembrolizumab....
The FDA has approved a new molecularly targeted therapeutic called fedratinib for treating certain patients with a rare blood...
The molecularly targeted therapeutic entrectinib is the second therapeutic of its kind approved by the FDA for use based...
The FDA approved a second molecularly targeted therapeutic for treating ROS1-positive lung cancer. The U.S. Food and Drug Administration...
The molecularly targeted therapeutic pexidartinib is the first ever systemic treatment approved by the FDA for the treatment of...
The FDA has expanded the use of the immunotherapeutic pembrolizumab to treat certain patients with esophageal cancer. The U.S....
A new antihormone agent darolutamide (Nubeqa) provides men with nonmetastatic prostate cancer a third option to control the disease...
The newly approved therapeutic is for patients with multiple myeloma that has either stopped responding to or has failed...